cas 18621-18-6|| where to buy azetidin-3-ol hydrochloride

Nombre del producto:azetidin-3-ol hydrochloride

IUPAC Name:azetidin-3-ol hydrochloride

Unidad de embalaje	Stock disponible	Precio($)
CM102453-100g	in stock	ũȐ
CM102453-500g	in stock	ȡƛǶ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 18621-18-6 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :18621-18-6; Fórmula molecular:C3H8ClNO; Punto de fusión:-; Código de sonrisas:Cl.OC1CNC1; Densidad:

: Número de catálogo:CM102453; Peso molecular:109.55; Punto de ebullición:; Nº Mdl:MFCD02683887; Almacenamiento:Store at room temperature.

: Azetidines; Azetidines are an important class of saturated four-membered nitrogen-containing heterocyclic compounds. The research hotspots related to this structure mainly focus on two aspects: one is the research of pharmaceutical chemistry; the other is related to chiral azetidines, using rigid azetidine compounds as chiral ligands for asymmetric catalytic reactions. Many nitrogen-containing heterocycles play important roles in drug structures, and in many cases small structural changes can improve ligand selectivity and pharmacokinetic properties.; Where to buy Azetidines; Where to buy ADC-Cytotoxins? Chemenu Provide Azetidines with high quality and competitive price. Contact us Now.

: Alicyclic Heterocycles; When the ends of the chains are joined together into a ring, cyclic compounds result; such substances often are referred to as carbocyclic or alicyclic compounds. Substitution of one or more of the ring carbon atoms in the molecules of a carbocyclic compound with a heteroatom gives a heterocyclic compound.

: Povorcitinib; Incyte announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib, an oral JAK1 inhibitor, in adult patients with prurigo nodularis (PN). These data were presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting.
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for PN.